Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2
Mehnmet Altay Unal, Omur Besbinar, Hasan Nazir, Gokce Yagmur Summak, Fatma Bayrakdar, Lucia Gemma Delogu, Tambay Taskin, Sibel Aysil Ozkan, Kamil Can Akcali, Acelya Yilmazer
doi:10.1101/2022.01.11.475889
Since the first cases the coronavirus disease caused by SARS-CoV-2 (COVID-19) reported in December 2019, worldwide continuous efforts have been placed both for the prevention and treatment of this infectious disease. As new variants of the virus emerge, the need for an effective antiviral treatment continues. The concept of preventing SARS-CoV-2 on both pre-entry and post-entry stages has not been much studied. Therefore, we compared the antiviral activities of three antiviral drugs which have been currently used in the clinic. In silico docking analyses and in vitro viral infection in Vero E6 cells were performed to delineate their antiviral effectivity when used alone or in combination. Both in silico and in vitro results suggest that the combinatorial treatment by favipiravir and umifenovir or camostat mesylate has more antiviral activity against SARS-CoV-2 rather than single drug treatment. These results suggest that inhibiting both viral entry and viral replication at the same time is much more effective for the antiviral treatment of SARS-CoV-2.
which have different mechanism of action can eventuate to an effective antiviral thearpy for SARS-CoV-2 infection. Preclincal and clinical studies are ongoing for drug combinations to combat SARS-CoV-2. The concept of preventing the virus on both pre-entry and post-entry stages has not been previously studied. Favipiravir is broad-spectrum antiviral pro-dug which inhibits viral replication by influencing the activiy of RdRp (Delang et al., 2018) . Favipiravir enters cell through cell membrane and phophoribosylated by Hypoxanthine Guanine Phosphoribosyltransferase (HGPRT) to become Favipiravir-ribose-5'-monophosphate (Favipiravir-RMP) (Naesens et al., 2013) . Favipiravir-RMP turns into Favipiravir-ribose-5-diphosphate (Favipiravir-RDP) and Favipiravir-ribose-5'-triphosphate (Favipiravir-RTP) respectively by phosphorylation. Favipiravir-RTP competes with purine basespredominantly GTP-to influence viral RdRp mediated viral replication (Furuta et al., 2013) . Favipiravir-RTP can base pair with both cysteine and uracil base pairs. In our study, the antiviral activity of favipiravir and umifenovir or favipiravir and camostat mesylate combinations are much more effective than mono drug threapies. Doi et al. showed that combination of favipiravir and another TMPRSS2 inhibitor nafamostat mesylate showed promising results indicating combinatorial treatment inhibits both viral replication and viral entry (Doi et al., 2020) . Therefore, it is reasonable to target both viral entry..
References
Breining, Frølund, Højen, Gunst, Staerke et al., Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety, Basic \& Clin. Pharmacol. \& Toxicol,
doi:10.1111/bcpt.13533Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir COVID-19: An Open-Label Control Study, Eng,
doi:10.1016/j.eng.2020.03.007Deng, Li, Zeng, Liu, Li et al., Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study, J. Infect,
doi:10.1016/j.jinf.2020.03.002Doi, Ikeda, Hayase, Moriya, Morimura et al., Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series, Crit. Care,
doi:10.1186/s13054-020-03078-zFrisch, Trucks, Schlegel, Scuseria, Robb et al., Gaussian G09. Gaussian Inc
Gunst, Staerke, Pahus, Kristensen, Bodilsen et al., Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2021.100849Halboub, Al-Maweri, Al-Soneidar, COVID-19: A review of the proposed pharmacological treatments, Eur. J. Pharmacol
Hoffmann, Hofmann-Winkler, Smith, Krüger, Arora et al., Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity, EBioMedicine,
doi:10.1016/j.ebiom.2021.103255Hoffmann, Kleine-Weber, Pöhlmann, A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells, Mol. Cell,
doi:10.1016/j.molcel.2020.04.022Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Hofmann-Winkler, Moerer, Alt-Epping, Bräuer, Büttner et al., Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation, Crit. care Explor,
doi:10.1097/CCE.0000000000000284Huang, Guan, Yang, Grange, Le et al., Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study, Res. Sq,
doi:10.21203/rs.3.rs-24667/v1Kitagawa, Arai, Iida, Mukai, Furukawa et al., A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19, Clin. Transl. Sci. n/a,
doi:10.1111/cts.13052Knoops, Kikkert, Van Den Worm, Zevenhoven-Dobbe, Van Der Meer et al., SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum, PLoS Biol,
doi:10.1371/journal.pbio.0060226Lan, Ge, Yu, Shan, Zhou et al., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature,
doi:10.1038/s41586-020-2180-5Letko, Marzi, Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, Nat. Microbiol,
doi:10.1038/s41564-020-0688-yLi, Li, Wang, Poirier, Huang, Multiple Ligand Simultaneous Docking (MLSD) and Its Applications to Fragment Based Drug Design and Drug Repositioning DISSERTATION
Lian, Xie, Lin, Huang, Zhao et al., Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study, Clin. Microbiol. Infect,
doi:10.1016/j.cmi.2020.04.026Murgolo, Therien, Howell, Klein, Koeplinger et al., SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development, PLOS Pathog,
doi:10.1371/journal.ppat.1009225Naesens, Guddat, Keough, Van Kuilenburg, Meijer et al., Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), Mol. Pharmacol,
doi:10.1124/mol.113.087247Pettersen, Goddard, Huang, Couch, Greenblatt et al., UCSF Chimera -A visualization system for exploratory research and analysis, J. Comput. Chem,
doi:10.1002/jcc.20084Pécheur, Lavillette, Alcaras, Molle, Boriskin et al., Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol, Biochemistry,
doi:10.1021/bi700181jTrott, Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem,
doi:10.1002/jcc.21334V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat. Rev. Microbiol,
doi:10.1038/s41579-020-00468-6Vankadari, Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.105998Wang, Cao, Zhang, Liu, Xu et al., The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro, Cell Discov,
doi:10.1038/s41421-020-0169-8Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Yuan, Pei, Lai, Binding Site Detection and Druggability Prediction of Protein Targets for Structure-Based Drug Design, Curr. Pharm. Des,
doi:10.2174/1381612811319120019{ 'institution': [{'name': 'bioRxiv'}],
'indexed': {'date-parts': [[2022, 1, 13]], 'date-time': '2022-01-13T03:42:21Z', 'timestamp': 1642045341087},
'posted': {'date-parts': [[2022, 1, 12]]},
'group-title': 'Pharmacology and Toxicology',
'reference-count': 0,
'publisher': 'Cold Spring Harbor Laboratory',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': [],
'accepted': {'date-parts': [[2022, 1, 12]]},
'abstract': '<jats:p>Since the first cases the coronavirus disease caused by SARS-CoV-2 (COVID-19) '
'reported in December 2019, worldwide continuous efforts have been placed both for the '
'prevention and treatment of this infectious disease. As new variants of the virus emerge, the '
'need for an effective antiviral treatment continues. The concept of preventing SARS-CoV-2 on '
'both pre-entry and post-entry stages has not been much studied. Therefore, we compared the '
'antiviral activities of three antiviral drugs which have been currently used in the clinic. '
'In silico docking analyses and in vitro viral infection in Vero E6 cells were performed to '
'delineate their antiviral effectivity when used alone or in combination. Both in silico and '
'in vitro results suggest that the combinatorial treatment by favipiravir and umifenovir or '
'camostat mesylate has more antiviral activity against SARS-CoV-2 rather than single drug '
'treatment. These results suggest that inhibiting both viral entry and viral replication at '
'the same time is much more effective for the antiviral treatment of SARS-CoV-2.</jats:p>',
'DOI': '10.1101/2022.01.11.475889',
'type': 'posted-content',
'created': {'date-parts': [[2022, 1, 13]], 'date-time': '2022-01-13T03:15:16Z', 'timestamp': 1642043716000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': ['Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2'],
'prefix': '10.1101',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-8607-5043',
'authenticated-orcid': False,
'given': 'Mehmet Altay',
'family': 'Unal',
'sequence': 'first',
'affiliation': []},
{'given': 'Omur', 'family': 'Besbinar', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-8423-751X',
'authenticated-orcid': False,
'given': 'Hasan',
'family': 'Nazir',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6274-3385',
'authenticated-orcid': False,
'given': 'Gokce Yagmur',
'family': 'Summak',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-7531-5080',
'authenticated-orcid': False,
'given': 'Fatma',
'family': 'Bayrakdar',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-2329-7260',
'authenticated-orcid': False,
'given': 'Lucia Gemma',
'family': 'Delogu',
'sequence': 'additional',
'affiliation': []},
{'given': 'Tambay', 'family': 'Taskin', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-7494-3077',
'authenticated-orcid': False,
'given': 'Sibel Aysil',
'family': 'Ozkan',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-7816-6938',
'authenticated-orcid': False,
'given': 'Kamil Can',
'family': 'Akcali',
'sequence': 'additional',
'affiliation': []},
{'given': 'Acelya', 'family': 'Yilmazer', 'sequence': 'additional', 'affiliation': []}],
'member': '246',
'container-title': [],
'original-title': [],
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.01.11.475889',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 1, 13]],
'date-time': '2022-01-13T03:15:17Z',
'timestamp': 1642043717000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 1, 12]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.1101/2022.01.11.475889',
'relation': {},
'published': {'date-parts': [[2022, 1, 12]]},
'subtype': 'preprint'}
